Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 23, 2020 08:05 ET | Source: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020

As previously reported, lenabasum did not meet its primary efficacy endpoint in the studyLenabasum was well tolerated with no new safety findingsExploratory post-hoc analyses revealed unexpectedly low...
June 22, 2020 08:05 ET | Source: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis

Topline data on schedule for Q3 2020Reduction in pulmonary exacerbations (PEx) as primary endpoint Study enrolled 426 participants regardless of CFTR mutation or background CFTR-targeting...